Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05601752 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05601752 · ClinicalTrials.gov record · last posted 2026-08-12

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Name: ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) — clinical trial record (NCT05601752)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorUSWM CT, LLC

Started2023-06-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.

Amendment record 9 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 9 times since 2022-10-31; most recent amendment 2026-02-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-12-17

Status change Recruiting→Active, Not Recruitingv8

2023-06-30

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT05601752
Lead Sponsor	USWM CT, LLC Collaborators: GOG Foundation
Conditions	Ovarian Cancer
Enrollment	66 participants
Start Date	2023-06-26
Primary Completion	2026-08-12 (estimated)
Study Completion	2026-08-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-12